Seven Fleet Capital Management LP Invests $510.42 Million in Compass Therapeutics, Inc. $CMPX

Seven Fleet Capital Management LP bought a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 233,066 shares of the company’s stock, valued at approximately $510,415,000. Seven Fleet Capital Management LP owned approximately 0.13% of Compass Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Artia Global Partners LP acquired a new stake in shares of Compass Therapeutics during the second quarter worth approximately $839,000. Bank of America Corp DE bought a new stake in Compass Therapeutics during the 2nd quarter worth approximately $1,242,000. Jupiter Topco LLC bought a new position in Compass Therapeutics in the 2nd quarter valued at $121,000. ADAR1 Capital Management LLC bought a new position in Compass Therapeutics in the 2nd quarter valued at $267,000. Finally, Canada Pension Plan Investment Board acquired a new position in Compass Therapeutics in the second quarter worth $352,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Stock Performance

NASDAQ CMPX opened at $2.43 on Thursday. The stock has a market capitalization of $437.62 million, a P/E ratio of -6.08 and a beta of 0.92. Compass Therapeutics, Inc. has a 52 week low of $1.61 and a 52 week high of $6.88. The stock has a fifty day moving average of $2.17 and a 200-day moving average of $3.50.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities research analysts forecast that Compass Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CMPX shares. Stifel Nicolaus set a $6.00 target price on Compass Therapeutics in a research note on Monday, June 1st. Piper Sandler upped their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Wall Street Zen cut shares of Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Compass Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $5.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.77.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.